Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free GNTA Stock Alerts

Genenta Science (GNTA) Competitors

Genenta Science logo
$1.26 +0.07 (+5.88%)
As of 08/21/2026 04:00 PM Eastern
Compare

GNTA vs. RANI, CUE, OTLK, KLRS, and BNR

Should you buy Genenta Science stock or one of its competitors? Genenta Science's main competitors and comparable companies include Rani Therapeutics (RANI), Cue Biopharma (CUE), Oncobiologics (OTLK), Kalaris Therapeutics (KLRS), and Burning Rock Biotech (BNR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genenta Science compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Genenta Science has lower revenue, but higher earnings than Rani Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rani Therapeutics$1.63M75.26-$29.67M-$0.27N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

In the previous week, Rani Therapeutics had 7 more articles in the media than Genenta Science. MarketBeat recorded 7 mentions for Rani Therapeutics and 0 mentions for Genenta Science. Rani Therapeutics' average media sentiment score of 0.37 beat Genenta Science's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Rani Therapeutics Neutral
Genenta Science Neutral

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rani Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 894.32%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Genenta Science's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rani TherapeuticsN/A -104.60% -65.17%
Genenta Science N/A N/A N/A

Summary

Rani Therapeutics beats Genenta Science on 8 of the 12 factors compared between the two stocks.

How does Genenta Science compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cue Biopharma had 7 more articles in the media than Genenta Science. MarketBeat recorded 7 mentions for Cue Biopharma and 0 mentions for Genenta Science. Cue Biopharma's average media sentiment score of 0.21 beat Genenta Science's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Cue Biopharma Neutral
Genenta Science Neutral

Cue Biopharma has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genenta Science has lower revenue, but higher earnings than Cue Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$27.47M6.34-$26.60M-$27.02N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Genenta Science has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Genenta Science's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-435.83% -620.06% -291.15%
Genenta Science N/A N/A N/A

Summary

Cue Biopharma and Genenta Science tied by winning 5 of the 10 factors compared between the two stocks.

How does Genenta Science compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Genenta Science has lower revenue, but higher earnings than Oncobiologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$1.35M71.24-$62.42M-$0.77N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

In the previous week, Oncobiologics had 13 more articles in the media than Genenta Science. MarketBeat recorded 13 mentions for Oncobiologics and 0 mentions for Genenta Science. Oncobiologics' average media sentiment score of 1.02 beat Genenta Science's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company Overall Sentiment
Oncobiologics Positive
Genenta Science Neutral

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oncobiologics currently has a consensus target price of $4.65, suggesting a potential upside of 618.48%. Given Oncobiologics' stronger consensus rating and higher possible upside, research analysts plainly believe Oncobiologics is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -254.82%
Genenta Science N/A N/A N/A

Oncobiologics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Oncobiologics beats Genenta Science on 7 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Kalaris Therapeutics?

Genenta Science (NASDAQ:GNTA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
Kalaris TherapeuticsN/AN/A-$43.44M-$2.02N/A

Genenta Science's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
Kalaris Therapeutics N/A -71.71%-42.95%

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Genenta Science's average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company Overall Sentiment
Genenta Science Neutral
Kalaris Therapeutics Neutral

Genenta Science has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 351.81%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Kalaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Summary

Kalaris Therapeutics beats Genenta Science on 6 of the 10 factors compared between the two stocks.

How does Genenta Science compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Genenta Science has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Genenta Science's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
Genenta Science N/A N/A N/A

Genenta Science has lower revenue, but higher earnings than Burning Rock Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.33-$7.92M-$0.82N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Burning Rock Biotech has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

In the previous week, Burning Rock Biotech's average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company Overall Sentiment
Burning Rock Biotech Neutral
Genenta Science Neutral

Summary

Burning Rock Biotech and Genenta Science tied by winning 4 of the 8 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNTA vs. The Competition

Export
MetricGenenta ScienceBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$29.73M$4.01B$7.37B$12.83B
Dividend YieldN/A3.64%2.53%10.78%
P/E RatioN/A11.62272.3324.21
Price / SalesN/A1,341.06625.2596.46
Price / CashN/A44.9429.0336.90
Price / Book0.9817.3811.256.42
Net Income-$7.39M-$22.72M$3.47B$348.89M
7 Day Performance-3.08%3.29%2.09%0.08%
1 Month Performance-23.64%8.23%6.64%3.88%
1 Year Performance-64.10%55.05%25.02%16.98%

Genenta Science Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNTA
Genenta Science
0.4547 of 5 stars		$1.26
+5.9%		N/A-64.1%$29.73MN/AN/A7
RANI
Rani Therapeutics
3.6691 of 5 stars		$0.91
+10.2%		$8.75
+861.5%		+40.9%$112.98M$4.88MN/A110
CUE
Cue Biopharma
0.5097 of 5 stars		$25.90
+0.8%		N/A-96.8%$109.43M$27.47MN/A60
OTLK
Oncobiologics
3.9722 of 5 stars		$0.71
+2.0%		$4.65
+551.3%		-75.9%$105.20M$1.35MN/A20
KLRS
Kalaris Therapeutics
2.8365 of 5 stars		$4.29
+6.5%		$18.75
+337.1%		+65.3%$102.15MN/AN/A110

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel